Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by The Goldman Sachs Group from $200.00 to $225.00 in a research note issued to investors on Thursday,Benzinga reports.

We recently compiled a list of the 12 Best Japanese Stocks To Buy in 2025. In this article, we are going to take a look at ...

Jenburkt Pharmaceuticals Limited, a 40-year-old pharmaceutical organization listed on the Bombay Stock Exchange and a pioneer ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Verona Pharma (NASDAQ:VRNA – Free Report) had its price target hoisted by Canaccord Genuity Group from $44.00 to $72.00 in a research note published on Wednesday,Benzinga reports. They currently have ...

There are two primary strategies investors use to research stocks: fundamental analysis and technical analysis. "Typically, ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

After back-to-back years of 20%-plus gains in 2023 and 2024, the S&P 500 is off to another strong start to 2025. However, the S&P 500's forward earnings multiple of 22 (as of Feb. 7) was also ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

PM; the BSE Smallcap and BSE Midcap indices were down 3.1% and 2.3%, respectively, as against 0.3% decline in the BSE Sensex.

Google, SoftBank invest in QuEras neutral atom quantum computer project Tech giants team up to fund cutting-edge quantum computing innovations ...

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...